Results 171 to 180 of about 345,077 (288)
Recommendations for raloxifene use in daily clinical practice in the Swiss setting [PDF]
Background/aim: Raloxifene is the first selective estrogen receptor modulator that has been approved for the treatment and prevention of osteoporosis in postmenopausal women in Europe and in the US. Although raloxifene reduces the risk of invasive breast
Birkhäuser, M. +9 more
core
Dual energy X-ray absorptiometry diagnostic discordance between Z scores and T scores in a young Iranian population [PDF]
Background: Dual-energy X-ray Absorptiometry (DXA) is considered the gold standard for non-invasive measurement of bone mass. T-scores and Z-scores are used to present the results of bone mass. The present study was designed to evaluate the discordance
Heidari, Benham +5 more
core +1 more source
The senescence of macrophages leads to a decrease in the expression of Sirtuin3 (Sirt3), which in turn aggravates the NLRP3 inflammasome activation and IL‐1β secretion, thereby promoting the aging‐related osteoporosis. Sirt3‐enriched apoptotic bodies (ABs‐Sirt3) generated through genetic editing approaches can alleviate skeletal aging by targeting ...
Yanglin Wu +7 more
wiley +1 more source
We report an electrochemical biosensor that employs biopanning‐derived affinity peptides as selective receptors on a multifunctional chitosan–zwitterionic–gold nanoparticle (CS–ZI–AuNPs) nanohydrogel interface. The CS–ZI–AuNPs nanohydrogel exhibits antifouling properties, abundant sites for stable peptide immobilization, and efficient electrochemical ...
Hyo Jeong Yang +6 more
wiley +1 more source
Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study - how useful is the current clinical gold standard for fracture risk? [PDF]
Abel, PD, Shah, SIA, Wilson, HCP
core +1 more source
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami +10 more
wiley +1 more source
Natural compounds regulate gut microbiota by improving microbial balance and increasing probiotics, which boost short‐chain fatty acid production to alleviate insulin resistance and inflammation. Additionally, they stimulate appetite‐suppressing hormones through bile acid signaling, while inhibiting pathogenic bacteria to repair intestinal barrier ...
Hongchao Yuan +7 more
wiley +1 more source
ABSTRACT Background and Aim This systematic review examined associations between vitamin D status and/or supplementation and functional outcomes (e.g., strength, performance, falls), with secondary reporting of biomechanical endpoints of human muscle, tendon, and bone.
Mohammad Soltani +2 more
wiley +1 more source
A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis [PDF]
Osteoporosis is a major cause of morbidity, mortality and resource cost amongst the elderly population. Hip fracture is the most serious of the osteoporotic fractures, with approximately 10-20% of patients dying within six months of sustaining a fracture.
Bernie O'Brien +3 more
core
Egg yolk hydrolysate shows moderate impact on osteoporosis in ovariectomized rats
Abstract BACKGROUND This study investigated the protective effect of egg yolk hydrolysate (FC) on osteoporosis in ovariectomized (OVX) rats, a well‐established model of postmenopausal bone loss. OVX rats were fed diets supplemented with 0.2% or 1% FC for 13 weeks.
Ilekuttige Priyan Shanura Fernando +4 more
wiley +1 more source

